Future of Parkinson's Disease Treatment Market

Parkinson’s disease therapeutic drugs act upon the central nervous system to control or reduce the symptoms of Parkinson’s disease. The global Parkinson’s disease treatment market is expected to reach USD 5.69 billion by 2022 from USD 4.24 billion in 2017, at a CAGR of 6.1%.

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=47265247

Globally, the Parkinson’s disease treatment market is witnessing a moderate growth due to factors such as increasing prevalence of Parkinson’s disease; rising geriatric population; and support for research on Parkinson’s disease.

Over the last few decades, key players operating in this market are focusing on offering new and innovative products. Based on drug class, the Parkinson’s disease therapeutic drugs market is segmented into carbidopa/levodopa dopamine receptor agonists, MAO-inhibitors, COMT-inhibitors, anticholinergics and other drugs. The carbidopa/levodopa segment is expected to register the highest CAGR during the forecast period. This is due to carbidopa/levodopa drugs are more potent and widely used in the treatment of Parkinson’s disease in comparison to other therapeutic drugs.

By distribution channel, the market is segmented into hospital pharmacies, retailer pharmacies, and online pharmacies. The online pharmacies segment is expected to register the highest growth rate during the forecast period. Advancements such as 24/7 availability, home delivery, and discount on medicines are driving factors for online pharmacies segment.

Talk To Our Research Analysts: http://www.marketsandmarkets.com/speaktoanalyst.asp?id=47265247

On the basis of patient care setting, the market is categorized into hospitals and clinics. The hospitals segment is estimated to grow at the fastest rate during the forecast period. The growth of this segment can be attributed to the availability of diagnostics laboratories in the hospital and the presence skilled neurologists.

The Parkinson’s disease treatment market is classified based on regions into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Presence key market players and rising aging population are the major factors driving the Parkinson’s disease treatment market in this region.

About MarketsandMarkets™:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
sales@marketsandmarkets.com

This release was published on openPR.